esketamine has been researched along with Depression in 124 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (5.65) | 24.3611 |
| 2020's | 117 (94.35) | 2.80 |
| Authors | Studies |
|---|---|
| Jamieson, C; Katz, EG; Levitan, B; Martynowicz, J; McNulty, P; Treichler, P | 1 |
| Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A | 1 |
| de la Vega Sánchez, D; López-Díaz, Á; Rendón de Lope, L | 1 |
| Daly, EJ; Drevets, WC; Hough, D; Jamieson, C; Lane, R; Lim, P; Manji, H; Ochs-Ross, R; Sanacora, G; Singh, JB; Steffens, DC; Wajs, E; Zhang, Y | 1 |
| Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G | 1 |
| McIntyre, RS | 1 |
| Asellus, P; Degerlund Maldi, K; Myléus, A; Norström, F | 1 |
| Bandeira, ID; Beanes, G; Caliman-Fontes, AT; Cardoso, TA; Carvalho, LP; Carvalho, MS; Correia-Melo, FS; Echegaray, M; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Machado, P; Magnavita, G; Mello, RP; Paixão, CS; Quarantini, LC; Sampaio, AS; Silva, SS; Vieira, F | 1 |
| Han, X; Lei, C; Li, Y; Liu, H; Tao, Z; Yang, Y; Yuan, X; Zhang, K; Zhang, W | 1 |
| Canuso, CM; Cooper, K; Daly, EJ; Freeman, MP; Jones, RR; Kornstein, SG; Nicholson, S | 1 |
| Dalla, C; Kokras, N; Megalokonomou, A; Pavlidi, P; Sofron, A | 1 |
| Cestac, P; Jullien, A; Montastruc, F; Taillefer de Laportalière, T; Yrondi, A | 2 |
| Chen, G; Chen, L; Daly, EJ; Drevets, WC; Fedgchin, M; Furey, ML; Lane, R; Li, X; Lim, P; Popova, V; Singh, JB; Zhang, Y | 1 |
| Horowitz, M; Moncrieff, J | 1 |
| Kasper, S; Lanzenberger, R; Naderi-Heiden, A; Praschak-Rieder, N; Unterholzner, J; Vanicek, T | 1 |
| Liu, D; Wang, H; Wang, Z; Wu, B; Yan, F; You, Y; Yuan, S; Zhang, F; Zhu, R; Zhu, X | 1 |
| Curran, HV; Freeman, TP; Grabski, M; van Laar, M; Waldron, J | 1 |
| Aloysi, A; Evers, A; Jha, MK; Klein, M; Murrough, J | 1 |
| Bouju, S; Codet, MA; Gaudré-Wattinne, E; Mekaoui, L; Rothärmel, M; Samalin, L; Sauvaget, A | 1 |
| Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza, LS; Souza-Marques, B; Vieira, F | 1 |
| Courtet, P; Lengvenyte, A; Olié, E; Strumila, R | 1 |
| Bahji, A; Vazquez, GH; Zarate, CA | 4 |
| Li, Y; Tian, Z; Wang, T; Weng, H; Xi, B; Yang, Z; Zhou, H | 1 |
| Krystal, JH; Murphy, E; Nikayin, S; Wilkinson, ST | 1 |
| Cooper, K; Drevets, WC; Floden, L; Hudgens, S; Jamieson, C; Popova, V; Singh, J | 1 |
| Fu, Y; Han, R; Ma, B; Sun, W; Wang, A; Wang, G; Wang, J; Zhou, Y | 1 |
| Honyashiki, M; Inoue, T; Terao, I | 1 |
| Kritzer, MD; Masand, PS; Pae, CU | 1 |
| Rosenman, S | 1 |
| Cunningham, ME; de Fontnouvelle, CA; Nikayin, S; Ostroff, RB; Rhee, TG; Sanacora, G; Wilkinson, ST | 1 |
| Kobayashi, H; Ohnishi, T; Wakamatsu, A | 1 |
| Gu, T; Jiang, G; Liu, Q; Liu, S; Wang, Y; Yin, A; Zhang, L | 1 |
| Borentain, S; Cabrera, P; Carmody, T; Daly, EJ; DiBernardo, A; Gogate, J; Jamieson, C; Popova, V; Trivedi, M; Wajs, E; Williamson, D | 1 |
| Bai, Y; Bi, XY; Cao, L; Liu, NN; Xin, Y; Xing, BH; Zhang, DX; Zhang, LM; Zhang, W; Zheng, WC | 1 |
| Cook, J; Halaris, A | 2 |
| Ceban, F; Di Vincenzo, JD; Ho, C; Lee, Y; Levinta, A; Lui, LMW; Mansur, RB; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM | 1 |
| Joca, SRL; Lisboa, SF; Sartim, AG; Silveira, KM; Vieira, L; Wegener, G | 1 |
| Monahan, K; Shepard, E; Weyandt, L | 1 |
| Daly, EJ; Gogate, JP; Kern Sliwa, JK; Manera, LS; Preskorn, SH; Starr, HL; Williamson, DJ; Winokur, A | 1 |
| Brendle, M; Malone, DC; Robison, R | 1 |
| Andriola, I; Barlati, S; Bassetti, R; Belletti, S; Bellomo, A; Bertolino, A; Chiaie, RD; Clerici, M; Conca, A; d'Andrea, G; De Fazio, P; De Filippis, S; Dell'Osso, B; di Giannantonio, M; Di Lorenzo, G; Di Mauro, S; Di Nicola, M; Fagiolini, A; Maina, G; Martiadis, V; Martinotti, G; McIntyre, RS; Nicolò, G; Nucifora, D; Olivola, M; Pettorruso, M; Rosso, G; Sani, G; Siracusano, A; Valchera, A; Vita, A | 1 |
| Joshi, K; Karkare, S; Lefebvre, P; Morrison, L; Nash, AI; Pilon, D; Shah, A; Zhdanava, M | 1 |
| Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U | 1 |
| Huang, X; Tao, Y; Xu, H | 1 |
| Daly, EJ; Jha, MK; Magharehabed, G; Trivedi, MH; Turkoz, I; Williamson, DJ | 1 |
| Kamphuis, J; Kutscher, M; Meij, AV; Schoevers, RA; Smith-Apeldoorn, SY; Veraart, JKE; Vischjager, M | 1 |
| Ahuja, S; Brendle, M; Malone, DC; Moore, C; Robison, R; Thielking, P; Valle, MD | 1 |
| Badulescu, S; Ceban, F; Di Vincenzo, JD; Ho, RC; Jawad, MY; McIntyre, RS; Mckenzie, A; Meshkat, S; Rosenblat, JD; Tabassum, A; Teopiz, KM | 1 |
| du Jardin, K; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G | 1 |
| Cheng, YJ; Lane, HY; Lin, CH | 1 |
| Chaki, S; Watanabe, M | 1 |
| Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G | 1 |
| Andriola, I; Barlati, S; Bassetti, R; Bertolino, A; Cavallotto, C; Chiappini, S; Clerici, M; d'Andrea, G; De Fazio, P; De Filippis, S; Dell'Osso, B; di Giannantonio, M; Di Lorenzo, G; Di Mauro, S; Di Nicola, M; Maina, G; Marcatili, M; Martinotti, G; McIntyre, RS; Nicolò, G; Nucifora, D; Pettorruso, M; Rosso, G; Sensi, SL; Vita, A; Zanardi, R | 1 |
| Armeni, P; Costa, F; Falivena, C; Rognoni, C | 1 |
| Feng, S; Jiang, M; Li, Q; Mao, M; Wen, Y; Xu, C; Yuan, H; Zhou, R | 1 |
| d'Andrea, G; Lorenzo, GD; Mancusi, G; Martinotti, G; McIntyre, RS; Pettorruso, M | 1 |
| Borentain, S; Daly, E; Macaluso, M; Nelson, JC; Salvadore, G; Sheehan, JJ; Singh, J; Trivedi, MH; Turkoz, I; Wilkinson, ST; Williamson, D | 1 |
| Arjmand, S; Joca, S; Landau, AM; Silva, NR; Vadstrup Pedersen, M; Wegener, G | 1 |
| Du, Y; Liu, B; Liu, Q; Xu, C; Zhang, L | 1 |
| Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A | 1 |
| Cooper, K; Daly, E; Drevets, WC; Jamieson, C; Popova, V; Rozjabek, HM; Singh, J | 1 |
| Chen, LN; Doherty, T; Drevets, WC; Fu, DJ; Lane, R; Morrison, RL; Popova, V; Sanacora, G; Wilkinson, ST; Zaki, N | 1 |
| Bernardo, WM; Floriano, I; Silvinato, A | 2 |
| Breeksema, JJ; Kamphuis, J; Kuin, B; Niemeijer, A; Schoevers, R; van den Brink, W; Veraart, J; Vermetten, E | 1 |
| Bai, ZH; Chen, L; Duan, KM; Gao, K; Li, QW; Mao, XY; Ping, AQ; Wang, SY; Xu, SY; Yang, SQ; Yang, ST; Zhou, YY | 1 |
| Bartolucci, G; Camardese, G; Di Nicola, M; Marcelli, I; Pepe, M; Sani, G; Simonetti, A | 1 |
| Andriola, I; Carullo, R; Chiappini, S; Clerici, M; d'Andrea, G; Di Lorenzo, G; Martiadis, V; Martinotti, G; McIntyre, RS; Pettorruso, M; Sani, G; Sensi, SL; Stefanelli, G; Vita, A; Zanardi, R | 1 |
| Caron-Lapointe, G; Joshi, K; Lefebvre, P; Pilon, D; Teeple, A; Zhdanava, M | 1 |
| De Wit, NCJ; Koning, MV; Stuiver, S; Van Verseveld, M; Van Waarde, JA | 1 |
| Andriola, I; Barlati, S; Bassetti, R; Carullo, R; Chiappini, S; Clerici, M; D'Andrea, A; d'Andrea, G; De Fazio, P; De Filippis, S; De Risio, L; Di Lorenzo, G; Di Nicola, M; Guidotti, R; Marcatili, M; Maria Dell'Osso, B; Martiadis, V; Martinotti, G; Marzetti, L; McIntyre, RS; Nicolò, G; Nucifora, D; Pettorruso, M; Rosenblat, JD; Rosso, G; Sensi, SL; Vita, A; Zanardi, R | 1 |
| Gan, S; Pan, Q; Song, Z; Yang, Q; Yang, S; Yin, Y; Yu, K; Zhang, B; Zuo, X | 1 |
| Cohen, D; Curiale, V; Jacquet, B; Laurent, I; Louchart De La Chapelle, S; Romani, S | 1 |
| d'Andrea, G; Di Lorenzo, G; Martinotti, G; McIntyre, RS; Pettorruso, M; Rhee, TG | 1 |
| Advenier-Iakovlev, E; Danon, M; De Maricourt, P; Estrade, I; Gaillard, R; Gorwood, P; Leroy, S; Mancusi, RL; Mekaoui, L; Perrain, R; Petit, AC; Poupon, D; Sylvestre, V; Vinckier, F | 1 |
| Chen, C; Liu, X; Mei, B; Wei, Q; Zhu, J | 1 |
| Chen, C; Chen, X; Feng, J; Hu, N; Jia, J; Liu, X; Wang, X; Xu, T; Yi, P; Zhang, C | 1 |
| Bitter, I; Buyze, J; Cebulla, K; Frey, R; Fu, DJ; Godinov, Y; Ito, T; Kambarov, Y; Llorca, PM; Messer, T; Mulhern-Haughey, S; Oliveira-Maia, AJ; Reif, A; Rive, B; von Holt, C; Young, AH | 1 |
| Harris, E | 1 |
| Corlett, PR; Hershenberg, R; Joormann, J; Kitay, BM; Macaluso, M; Martinez-Kaigi, V; Murphy, E; Nikayin, S; Rhee, TG; Sanacora, G; Shelton, RC; Thase, ME; Wilkinson, ST | 1 |
| Endo, K; Kodama, W; Terao, I; Tsuge, T | 1 |
| Pal, H | 1 |
| Jauhar, S; Morrison, P | 1 |
| Baldwin, DS; McAllister-Williams, RH; McShane, R; Stone, JM; Taylor, D; Winstock, AR; Young, AH | 1 |
| Lavretsky, H; Roose, SP | 1 |
| Araújo-de-Freitas, L; Bandeira, ID; Caliman-Fontes, AT; Cavalcanti, DE; Correia-Melo, FS; Del-Porto, JA; Echegaray, MVF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Loo, C; Magnavita, G; Mello, RP; Nakahira, C; Quarantini, LC; Sampaio, AS; Sarin, LM; Silva, SS; Tuena, MA; Turecki, G; Vieira, F | 1 |
| Barbui, C; Gastaldon, C; Ostuzzi, G; Papola, D | 1 |
| Li, P; Li, Q; Liu, C; Liu, P; Peng, S; Shi, X; Yan, H; Zhang, Y | 1 |
| Witkin, JM | 1 |
| De Berardis, D; Di Giannantonio, M; Fornaro, M; Fraticelli, S; Kim, YK; Martinotti, G; Orsolini, L; Perna, G; Pompili, M; Serafini, G; Tomasetti, C; Valchera, A; Vellante, F; Volpe, U | 1 |
| Chang, L; Hashimoto, K; Wei, Y | 1 |
| Daly, EJ; Drevets, WC; Fedgchin, M; Hough, D; Mathews, M; Popova, V; Singh, JB | 1 |
| Cristea, IA; Naudet, F | 1 |
| Turner, EH | 1 |
| Barbosa, MG; Delfino, RS; Jackowski, AP; Sarin, LM | 1 |
| Hashimoto, K | 1 |
| Citrome, L; DiBernardo, A; Singh, J | 1 |
| Liu, P; Peng, S; Wang, J; Wang, Y; Xu, F; Xu, X | 1 |
| Kolar, D | 1 |
| Ross, EL; Soeteman, DI | 1 |
| Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH | 1 |
| Blackowicz, M; Cooper, K; Drevets, WC; Fedgchin, M; Floden, L; Hudgens, S; Jamieson, C; Lane, R; Popova, V; Singh, J | 1 |
| Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J | 1 |
| Chen, G; Li, X; Wang, J; Wang, T; Xu, X; Xu, Z; Yang, S; Zhou, X | 1 |
| Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA | 1 |
| Desai, U; Guglielmo, A; Kirson, NY; Le, HH; Shawi, M; Sheehan, JJ; Spittle, T; Tseng-Tham, J | 1 |
| Borentain, S; Canuso, CM; Cepeda, MS; Daly, EJ; Drevets, WC; Lane, R; Manji, HK; Mathews, M; Popova, V | 1 |
| Correia-Melo, FS; Jesus-Nunes, AP; Mello, RP; Quarantini, LC; Sampaio, AS; Souza-Marques, B | 1 |
| Brula, AQ; Sanders, B | 1 |
| Ekstrand, J | 1 |
| Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Magnavita, GM; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza-Marques, B; Telles, M; Vieira, F | 1 |
| Bentzley, BS; Heifets, BD; Schatzberg, AF; Williams, N | 1 |
| Abreu, N; Araújo-de-Freitas, L; Beanes, G; Cardoso, TL; Correia-Melo, FS; Echegaray, MV; França, RJAF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Lucchese, AC; Magnavita, G; Marback, R; Mello, RP; Mendonça-Filho, E; Quarantini, LC; Rabanea, T; Santos-Lima, C; Souza-Marques, B; Teles, M; Vieira, F | 1 |
| Marom, A; Rosca, P | 1 |
| Cao, B; Cha, DS; Gill, H; Ho, RC; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Ng, J; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM | 1 |
| Borentain, S; Daly, EJ; Fedgchin, M; Ionescu, DF; Salvadore, G; Singh, JB; Starr, HL; Thase, ME; Trivedi, MH; Turkoz, I | 1 |
| Hashimoto, K; Yang, C | 1 |
| Chang, L; Dong, C; Fujita, Y; Hashimoto, K; Pu, Y; Qu, Y; Ren, Q; Wang, SM; Xiong, Z; Zhang, K | 1 |
| Schatzberg, AF | 1 |
29 review(s) available for esketamine and Depression
| Article | Year |
|---|---|
[Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male | 2021 |
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2022 |
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Male | 2022 |
Long-term safety of ketamine and esketamine in treatment of depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Randomized Controlled Trials as Topic | 2022 |
The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Diversity inclusion in clinical trials investigating esketamine for depression: A systematic review.
Topics: Adult; Depression; Female; Humans; Ketamine | 2023 |
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin | 2022 |
Letter to the editor about "Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis".
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression: A Systematic Literature Review and Case Series.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Serotonin Syndrome | 2022 |
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.
Topics: Anhedonia; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Psychopathology | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate; Sarcosine | 2023 |
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States | 2023 |
Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis."
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Reporting of harms in clinical trials of esketamine in depression: a systematic review.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depression; Humans; Ketamine | 2023 |
The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2023 |
The use of esketamine in the treatment of patients with oral antidepressant-resistant depression: systematic review and meta-analysis.
Topics: Brazil; Depression; Humans | 2023 |
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis
Topics: Adult; Antidepressive Agents; Aripiprazole; Depression; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Lithium; Network Meta-Analysis | 2024 |
mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects.
Topics: Animals; Antidepressive Agents; Cyclohexanes; Depression; Excitatory Amino Acid Antagonists; Humans; Ketamine; Receptors, Metabotropic Glutamate | 2020 |
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
Topics: Administration, Intranasal; Antidepressive Agents; Clinical Trials as Topic; Databases, Factual; Depression; Depressive Disorder, Major; Drug Compounding; Glutamic Acid; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate; Suicide Prevention; Synaptic Transmission; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2020 |
A historical review of antidepressant effects of ketamine and its enantiomers.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Stereoisomerism; Treatment Outcome | 2020 |
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Gastrointestinal Microbiome; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate; Spleen | 2020 |
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine | 2021 |
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2021 |
Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials.
Topics: Depression; Dizziness; Humans; Hypesthesia; Ketamine; Nausea; Paresthesia; Randomized Controlled Trials as Topic; Vertigo | 2022 |
Intranasal esketamine: From origins to future implications in treatment-resistant depression.
Topics: Administration, Intranasal; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
[ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT].
Topics: Administration, Intranasal; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Risk Management | 2021 |
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
27 trial(s) available for esketamine and Depression
| Article | Year |
|---|---|
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Japan; Ketamine; Prospective Studies; Treatment Outcome | 2021 |
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depression; Double-Blind Method; Drug Therapy, Combination; Humans; Ketamine; Middle Aged; Nasal Sprays; Treatment Outcome; Young Adult | 2022 |
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
Topics: Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Nasal Sprays; Treatment Outcome | 2022 |
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Topics: Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Treatment Outcome | 2022 |
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
Topics: Adult; Antidepressive Agents; Depression; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Patient Health Questionnaire; Treatment Outcome | 2022 |
Effect of esketamine on perioperative depressive symptoms in major surgery patients (PASSION II): study protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; China; Depression; Humans; Ketamine; Middle Aged; Randomized Controlled Trials as Topic; Young Adult | 2022 |
Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Factor Analysis, Statistical; Humans; Ketamine; Placebo Effect; Treatment Outcome | 2022 |
Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Treatment Outcome | 2022 |
Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Treatment Outcome | 2023 |
Evaluation of clinical effects of Esketamine on depression in patients with missed miscarriage: A randomized, controlled, double-blind trial.
Topics: Abortion, Spontaneous; Depression; Double-Blind Method; Female; Humans; Pregnancy; Propofol | 2023 |
Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Treatment Outcome | 2023 |
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
Topics: Antidepressive Agents; Depression; Health Status; Humans; Middle Aged; Nasal Sprays; Quality of Life | 2023 |
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Quality of Life; Treatment Outcome | 2023 |
Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: A randomized, double-blind, controlled clinical study.
Topics: Cesarean Section; Depression; Double-Blind Method; Female; Humans; Ketamine; Postpartum Period; Pregnancy | 2023 |
Effect of postoperative application of esketamine on postoperative depression and postoperative analgesia in patients undergoing pancreatoduodenectomy: a randomized controlled trial protocol.
Topics: Analgesia; Depression; Humans; Pain; Pancreaticoduodenectomy; Postoperative Complications; Prospective Studies; Randomized Controlled Trials as Topic; Serotonin; Sufentanil; Tumor Necrosis Factor-alpha | 2023 |
Influence of low-dose esketamine on postoperative depressive symptoms in patients with breast cancer (EASE): study protocol for a randomised controlled trial.
Topics: Breast Neoplasms; Depression; Double-Blind Method; Female; Humans; Mastectomy; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Topics: Antidepressive Agents; Delayed-Action Preparations; Depression; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Nasal Sprays; Quetiapine Fumarate; Recurrence; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Single-Blind Method; Treatment Outcome | 2023 |
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.
Topics: Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Suicidal Ideation | 2023 |
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Japan; Ketamine; Treatment Outcome | 2020 |
Effect of Pretreatment of S-Ketamine On Postoperative Depression for Breast Cancer Patients.
Topics: Breast Neoplasms; Depression; Double-Blind Method; Female; Humans; Ketamine; Pain, Postoperative | 2021 |
Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Adult; Depression; Humans; Ketamine; Nasal Sprays; Treatment Outcome | 2020 |
Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression After Laparoscopic Total Hysterectomy.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Carcinoma; Depression; Depressive Disorder; Double-Blind Method; Female; Humans; Hysterectomy; Ketamine; Middle Aged; Pain Measurement; Pain, Postoperative; Serotonin; Uterine Cervical Neoplasms | 2020 |
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Patient Health Questionnaire; Treatment Outcome | 2021 |
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine | 2021 |
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Topics: Adult; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Humans; Ketamine; Treatment Outcome | 2021 |
68 other study(ies) available for esketamine and Depression
| Article | Year |
|---|---|
U.S. Food and Drug Administration's Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant
Topics: Antidepressive Agents; Depression; Double-Blind Method; Drug Development; Humans; Ketamine; Nasal Sprays; United States; United States Food and Drug Administration | 2022 |
Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: Towards registry-based surveillance systems.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Registries; Treatment Outcome | 2022 |
Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Middle Aged | 2022 |
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression.
Topics: Adult; Cost-Benefit Analysis; Depression; Electroconvulsive Therapy; Humans; Ketamine; Quality-Adjusted Life Years | 2021 |
Efficacy and safety of repeated esketamine intravenous infusion in the treatment of treatment-resistant depression: A case series.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamine | 2022 |
How to deprescribe esketamine in resistant depression? A point of view after first clinical uses.
Topics: Deprescriptions; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; Recurrence; Treatment Outcome | 2022 |
Esketamine: uncertain safety and efficacy data in depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder.
Topics: Antidepressive Agents; Borderline Personality Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Impulsive Behavior; Ketamine; Suicidal Ideation | 2022 |
S-Ketamine Exerts Antidepressant Effects by Regulating Rac1 GTPase Mediated Synaptic Plasticity in the Hippocampus of Stressed Rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Disease Models, Animal; GTP Phosphohydrolases; Hippocampus; Ketamine; Neuronal Plasticity; rac1 GTP-Binding Protein; Rats; Stress, Psychological | 2023 |
Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees.
Topics: Adolescent; Adult; Antidepressive Agents; Cross-Sectional Studies; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Perception; Young Adult | 2022 |
Antidepressant effect of prolonged twice-weekly intranasal esketamine treatments after nonresponse to electroconvulsive therapy in a patient with treatment-resistant depression.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Ketamine | 2022 |
Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.
Topics: Administration, Intranasal; Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Nasal Sprays | 2022 |
Esketamine alleviates postoperative depression-like behavior through anti-inflammatory actions in mouse prefrontal cortex.
Topics: Animals; Anti-Inflammatory Agents; Depression; Humans; Ketamine; Mice; NF-kappa B; Prefrontal Cortex | 2022 |
A letter to the editor, associated with the article entitled "Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium" by Vázquez et al. (
Topics: Antidepressive Agents; Antipsychotic Agents; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Ketamine; Lithium; Psychopharmacology | 2022 |
Intranasal esketamine for depression: Not so special K.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic.
Topics: Animals; Antidepressive Agents; Autophagy; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Depressive Disorder, Major; Ketamine; Lipopolysaccharides; Mice; TOR Serine-Threonine Kinases | 2022 |
S-ketamine administration in pregnant mice induces ADHD- and depression-like behaviors in offspring mice.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Depression; Female; Humans; Ketamine; Mice; Pregnancy; Swimming | 2022 |
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
Topics: Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Dopamine; Humans; Ketamine; N-Methylaspartate | 2022 |
Decreased sensitivity to antidepressant drugs in Wistar Hannover rats submitted to two animal models of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Escitalopram; Fluoxetine; Imipramine; Models, Animal; Rats; Rats, Wistar; Swimming | 2023 |
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dizziness; Humans; Ketamine; Nasal Sprays; Nausea; Vertigo | 2022 |
Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates.
Topics: Cost-Benefit Analysis; Depression; Humans; Ketamine; Nasal Sprays; Quality-Adjusted Life Years | 2022 |
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2022 |
Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Nasal Sprays; United States | 2022 |
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Female; Humans; Male; Retrospective Studies | 2022 |
Single dose S-ketamine rescues transcriptional dysregulation of Mtor and Nrp2 in the prefrontal cortex of FSL rats 1 hour but not 14 days post dosing.
Topics: Animals; Depression; Depressive Disorder, Major; Disease Models, Animal; Prefrontal Cortex; Rats; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2022 |
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Multicenter Studies as Topic; Observational Studies as Topic; Prospective Studies; Treatment Outcome | 2022 |
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy.
Topics: Antidepressive Agents; Cost-Benefit Analysis; Depression; Depressive Disorder, Major; Humans; Nasal Sprays; Quality-Adjusted Life Years; Reproducibility of Results; Serotonin and Noradrenaline Reuptake Inhibitors | 2023 |
The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Inflammation; Ketamine | 2023 |
Sex and Estrous Cycle Are Not Mediators of S-Ketamine's Rapid-Antidepressant Behavioral Effects in a Genetic Rat Model of Depression.
Topics: Animals; Antidepressive Agents; Depression; Estrous Cycle; Female; Ketamine; Male; Rats | 2023 |
Antidepressant effects of repeated s-ketamine administration as NMDAR Antagonist: Involvement of CaMKIIα and mTOR signaling in the hippocampus of CUMS mice.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Hippocampus; Receptors, Glutamate; Stress, Psychological; TOR Serine-Threonine Kinases | 2023 |
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Comorbidity; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Retrospective Studies; Substance-Related Disorders | 2023 |
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Patient Outcome Assessment | 2023 |
Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients With Chronic Treatment-resistant Depression: A 12-Week Case Series.
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans | 2023 |
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
Topics: Aged; Antidepressive Agents; Depression; Double-Blind Method; Humans; Ketamine; Retrospective Studies; Treatment Outcome | 2023 |
Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Insurance; Male; Middle Aged; Nasal Sprays | 2023 |
[IV esketamine for patients with a treatment-resistant depression].
Topics: Antidepressive Agents; Depression; Electroconvulsive Therapy; Humans; Ketamine | 2023 |
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Machine Learning; Reproducibility of Results; Retrospective Studies; Treatment Outcome | 2023 |
Esketamine for resistant depression in older people with cognitive impairment: A case report.
Topics: Aged; Antidepressive Agents; Cognitive Dysfunction; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression.
Topics: Bridge Therapy; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Early effects predict trajectories of response to esketamine in treatment-resistant depression.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Longitudinal Studies; Treatment Outcome | 2023 |
Exploring the role of esketamine in alleviating depressive symptoms in mice via the PGC-1α/irisin/ERK1/2 signaling pathway.
Topics: Animals; Antidepressive Agents; Depression; Fibronectins; Hippocampus; MAP Kinase Signaling System; Mice; Mice, Knockout; Muscle, Skeletal | 2023 |
Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Quetiapine Fumarate; Treatment Outcome | 2023 |
In treatment-resistant depression, adding esketamine nasal spray to an oral antidepressant improved symptoms at 28 days.
Topics: Antidepressive Agents; Depression; Double-Blind Method; Ketamine; Nasal Sprays | 2019 |
Esketamine for treatment resistant depression.
Topics: Administration, Intranasal; Administration, Oral; Antidepressive Agents; Depression; Drug Approval; Drug Therapy, Combination; Humans; Ketamine; United States; United States Food and Drug Administration | 2019 |
Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential.
Topics: Depression; Double-Blind Method; Humans; Ketamine; Registries; Suicide | 2019 |
The Efficacy and Safety of Esketamine for the Treatment-Resistant Depression in Older Adults: Comments on TRANSFORM-3 Trial Results.
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays | 2020 |
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Drug Approval; Evidence-Based Medicine; Humans; Infusions, Intravenous; Ketamine; United States; United States Food and Drug Administration | 2019 |
Approval of esketamine for treatment-resistant depression.
Topics: beta-Cyclodextrins; Depression; Depressive Disorder, Treatment-Resistant; Drug Combinations; Humans; Ketamine; Pregnanolone; United States; United States Food and Drug Administration | 2020 |
Approval of esketamine for treatment-resistant depression - Authors' reply.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Approval of esketamine for treatment-resistant depression - Author's reply.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Pregnancy; Suicide, Attempted | 2020 |
Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: A case report.
Topics: Abdominal Neoplasms; Aged; Antidepressive Agents; Depression; Humans; Ketamine; Male; Pain; Terminally Ill; Treatment Outcome | 2020 |
Long-term treatment of depression with intranasal esketamine: Is it justified?
Topics: Administration, Intranasal; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2020 |
Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.
Topics: Cost-Benefit Analysis; Depression; Humans; Ketamine; Nasal Sprays; United States | 2020 |
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays | 2021 |
Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Topics: Adult; Antidepressive Agents; Anxiety; Anxiety Disorders; Comorbidity; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Retrospective Studies | 2021 |
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression.
Topics: Administration, Oral; Depression; Humans; Ketamine; Nasal Sprays; Standard of Care | 2021 |
Comments to Drs. Bahji, Vazquez, and Zarate.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Letter to the editor - Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; Random Allocation | 2021 |
Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2021 |
Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al.
Topics: Analgesics, Opioid; Antidepressive Agents; Depression; Ketamine | 2021 |
Is (S)-norketamine an alternative antidepressant for esketamine?
Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine | 2019 |
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Dose-Response Relationship, Drug; Ketamine; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Prepulse Inhibition; Receptors, N-Methyl-D-Aspartate; Saline Solution; Stress, Psychological | 2019 |
A Word to the Wise About Intranasal Esketamine.
Topics: Administration, Intranasal; Antidepressive Agents; Depression; Double-Blind Method; Ketamine; Nasal Sprays | 2019 |